ETBRIUN Trademark

Trademark Overview

On Wednesday, April 24, 2019, a trademark application was filed for ETBRIUN with the United States Patent and Trademark Office. The USPTO has given the ETBRIUN trademark a serial number of 88399563. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 3, 2023. This trademark is owned by Glaxo Group Limited. The ETBRIUN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
etbriun

General Information

Serial Number88399563
Word MarkETBRIUN
Filing DateWednesday, April 24, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 3, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 7, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 9, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
GB

Trademark Events

Event DateEvent Description
Monday, April 3, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 3, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, August 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 1, 2022SOU EXTENSION 5 GRANTED
Thursday, July 28, 2022SOU EXTENSION 5 FILED
Thursday, July 28, 2022TEAS EXTENSION RECEIVED
Saturday, March 5, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 4, 2022SOU EXTENSION 4 GRANTED
Thursday, February 24, 2022SOU EXTENSION 4 FILED
Friday, March 4, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, February 24, 2022TEAS EXTENSION RECEIVED
Tuesday, July 20, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 16, 2021SOU EXTENSION 3 GRANTED
Friday, July 16, 2021SOU EXTENSION 3 FILED
Friday, July 16, 2021TEAS EXTENSION RECEIVED
Thursday, February 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 2, 2021SOU EXTENSION 2 GRANTED
Tuesday, February 2, 2021SOU EXTENSION 2 FILED
Tuesday, February 2, 2021TEAS EXTENSION RECEIVED
Friday, August 14, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 12, 2020SOU EXTENSION 1 GRANTED
Wednesday, August 12, 2020SOU EXTENSION 1 FILED
Wednesday, August 12, 2020TEAS EXTENSION RECEIVED
Tuesday, March 3, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 7, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 7, 2020PUBLISHED FOR OPPOSITION
Wednesday, December 18, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, December 5, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 30, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 30, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 30, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 13, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 13, 2019NON-FINAL ACTION E-MAILED
Thursday, June 13, 2019NON-FINAL ACTION WRITTEN
Monday, June 10, 2019ASSIGNED TO EXAMINER
Thursday, May 9, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, April 27, 2019NEW APPLICATION ENTERED

Related Keywords

etbriun pharmaceutical treatment preparations diseases disorders substances respiratory oncological genitourinary neurological